Blastic plasmacytoid dendritic cell neoplasm (BPDCN) arising in the setting of polycythemia vera (PV): An illustration of the emerging role of flow cytometry analysis in monitoring progression of myeloproliferative neoplasms
Siba El Hussein,
Mariko Yabe,
Wei Wang,
Naveen Pemmaraju,
Sanam Loghavi,
Fatima Zahra Jelloul,
Hong Fang,
L. Jeffrey Medeiros,
W. Richard Burack,
Andrew G. Evans,
Jane L. Liesveld,
John M. Bennett
Affiliations
Siba El Hussein
Department of Pathology University of Rochester Medical Center Rochester New York United States
Mariko Yabe
Hematopathology Service Department of Pathology and Laboratory Medicine Memorial Sloan Kettering Cancer Center New York New York United States
Wei Wang
Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston Texas United States
Naveen Pemmaraju
Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas United States
Sanam Loghavi
Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston Texas United States
Fatima Zahra Jelloul
Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston Texas United States
Hong Fang
Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston Texas United States
L. Jeffrey Medeiros
Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston Texas United States
W. Richard Burack
Department of Pathology University of Rochester Medical Center Rochester New York United States
Andrew G. Evans
Department of Pathology University of Rochester Medical Center Rochester New York United States
Jane L. Liesveld
Department of Medicine & The Wilmot Cancer Institute University of Rochester Medical Center Rochester New York United States
John M. Bennett
Department of Pathology University of Rochester Medical Center Rochester New York United States
Abstract This report highlights the value of flow cytometry analysis, particularly in the setting of myeloproliferative neoplasms showing features of progression, as neoplastic plasmacytoid dendritic cell (PDC) proliferations may be present, representing either a clonal expansion of mature PDCs related to the underlying myeloproliferative neoplasm or transformation to blastic plasmacytoid dendritic cell neoplasm (BPDCN). BPDCN should always be considered in patients with myeloid neoplasms in progression and/or who develop new cutaneous findings, as it may prompt change of management.
